<DOC>
	<DOCNO>NCT02955121</DOCNO>
	<brief_summary>Randomized control study examine physician use pharmacogenetic information patient receive antiplatelet medication percutaneous coronary intervention ( PCI ) .</brief_summary>
	<brief_title>IU Health Krannert Personalized Medicine Study</brief_title>
	<detailed_description>The study randomize patient complete PCI prescribe dual antiplatelet therapy genotype guide arm , CYP2C19 pharmacogenetic testing perform standard therapy arm without genetic testing . The study examine impact pharmacogenetic test physician medication choice clinical outcome .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Platelet Aggregation Inhibitors</mesh_term>
	<criteria>Patients ischemic heart disease , prescribe dual antiplatelet therapy percutaneous coronary intervention ( PCI ) . Enrollment occur index hospitalization outpatient visit cath lab procedure . Pregnant breastfeeding . Unwilling unable , opinion investigator , comply instruction prescribe medicine . Prior know allergy intolerance clopidogrel .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Cytochrome P-450 CYP2C19</keyword>
	<keyword>Pharmacogenetics</keyword>
	<keyword>Platelet Aggregation Inhibitors</keyword>
	<keyword>Percutaneous Coronary Intervention</keyword>
</DOC>